A startup called DeNovo Sciences is betting that a tiny blood-testing chip could one day reduce the need for traditional biopsies in some cancer cases. The idea is simple to describe but hard to execute: instead of removing a piece of tissue from the body, the company wants to find circulating tumor cells, or cancer cells that have broken away from a tumor and entered the bloodstream. Its approach uses a microfluidic chip, a device that channels small amounts of blood through microscopic pathways, to detect, separate, and capture those rare cells from whole blood. If the technology works as intended, doctors might be able to spot cancer earlier, potentially even before a primary tumor is visible through standard methods. That would matter because early detection often gives patients more treatment options and better odds. DeNovo is not alone in this race: several research groups and diagnostics companies have been working on blood-based cancer detection systems for years. What sets this story apart is the ambition to turn a difficult laboratory concept into a practical instrument-and-reagent system that could fit into real-world cancer care.
A Blood Test Instead of a Tissue Sample
For many cancers, a biopsy remains the standard way to confirm a diagnosis. In a biopsy, doctors remove a small sample of tissue and examine it for signs of cancer, a process that can be painful, invasive, and sometimes difficult depending on where the suspected tumor sits in the body.
DeNovo Sciences is pursuing a different route. Its chip is designed to work with peripheral whole blood, meaning an ordinary blood sample drawn from circulation rather than tissue taken from a tumor site. The goal is to detect cancer cells in that blood before they spread widely, or metastasize, which is when cancer moves from its original site to other parts of the body.
How a Microfluidic Chip Tries to Find Rare Cells
Think of the chip like a highly selective sieve built onto a miniature plumbing system. Blood flows through tiny channels, and the device is engineered to help isolate the extremely small number of tumor cells that may be mixed among millions of normal blood cells.
That challenge is the heart of the technology. Circulating tumor cells are rare, so any useful test has to do three things well: find them, separate them cleanly from the rest of the sample, and capture them for analysis. DeNovo says its microfluidic chip is meant to perform that chain of tasks in a single platform.
Why So Many Groups Are Chasing This Idea
DeNovo is entering a crowded and scientifically active field. The source notes that microfluidic chips for capturing cancer cells in blood have been studied at multiple research institutions for several years, showing that the concept has moved beyond a one-off experiment.
Other companies were also named as developers of increasingly sophisticated cancer-cell detection tools, including Veridex, a diagnostic subsidiary of Johnson & Johnson, as well as CytoScale Diagnostics LLC and On-Q-ity. These systems are aimed not only at detection, but also at helping guide treatment decisions and monitor how patients respond over time. In plain terms, a blood-based test could act less like a single snapshot and more like a repeatable check-in.
The Big Promise and the Big Unknowns
The appeal of a blood test for cancer is obvious. Drawing blood is generally easier and less risky than removing tissue, and it can be repeated more often, which could make it useful for screening, follow-up, or tracking how a tumor changes during treatment.
But the source also makes clear that there were limited details available about DeNovo's specific test. That makes it hard to judge how the company planned to distinguish its technology from competing approaches already in development. A request for an interview, according to the source, was not returned, leaving important questions unanswered about performance, accuracy, and what kinds of cancers the chip was designed to detect.
From Research Tool to Real Product
Turning a promising chip into a medical product is a much bigger task than building a working prototype. A company needs an instrument, reagents, repeatable manufacturing, and evidence that the system works reliably with real patient samples, not just idealized lab conditions.
That is why the story framed DeNovo's effort partly as a fundraising and commercialization challenge. The company hoped to raise money to move its instrument system and reagent kit forward, suggesting it was still at a stage where technical promise had to be matched by business execution. In diagnostics, those two tracks often rise or fall together.
The Market Was Already Taking Shape
The article placed DeNovo's work in the context of a larger diagnostic boom. According to BCC Research, imaging tests, genetic assays, and cellular analysis tools together made up a broad cancer detection and diagnosis pipeline expected to contribute to a market worth $5.3 billion in 2015.
That figure helps explain why so many companies were trying to improve cancer testing. A successful blood-based platform would not just offer a scientific advance; it could also claim a place in a large and growing clinical market where earlier detection and better monitoring are both prized. Still, market size alone does not prove clinical value, and any new test would need to show that it meaningfully improves care.
Why This Matters
Stories like this matter because they capture a key shift in medicine: moving from invasive sampling toward liquid biopsy-style approaches, where doctors learn about disease through blood and other body fluids. Even when the term liquid biopsy is not used explicitly, that is the broader idea behind technologies that search blood for tumor cells.
If companies like DeNovo succeed, patients could face fewer painful procedures, doctors might catch disease sooner, and treatment could become easier to adjust over time. If they fail, the reasons will likely be familiar ones in diagnostics: the biology is messy, rare-cell detection is hard, and clinical proof demands more than a compelling concept. Either way, this is the kind of work that shows how biochips are trying to move from elegant engineering to practical medicine.
The next chapter would depend on details the source did not provide: validation data, cancer types targeted, and whether the chip could outperform or complement existing tests. Even so, the direction of travel was clear. Researchers and companies alike were pushing toward a future where a vial of blood could reveal what once required a needle, a scalpel, or a difficult tissue sample.